Feed / MRVI

Maravai LifeSciences Holdings, Inc.

MRVI

Healthcare · 6.52 -3.5% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Maravai LifeSciences Holdings, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company-3.5% todayVolume comparison unavailable
Market group0 of 26 activeIndustrial & Healthcare Solutions · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • MRVI's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if MRVI's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • MRVI's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations320
Usable filing statements108
Verified relationships3
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case
  • Latest annual revenue changed -28.3% year over year.
  • Operating margin changed -25.0 percentage points in the latest annual period.
  • Net margin changed -14.5 percentage points in the latest annual period.
  • Diluted shares increased 4.7% in the latest annual period.
  • Credit and interest rates has repeated adverse evidence across 4 filings.
  • Demand and volume has repeated adverse evidence across 4 filings.
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
  • Restructuring and cost reductions has repeated adverse evidence across 4 filings.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 11, 2026

6.52
6m+80.6%12m+173.9%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$799.2M+181.3%$1.56
2022-12-31$883.0M+10.5%$1.67-1.0%
2023-12-31$288.9M-67.3%$-0.90-48.3%
2024-12-31$259.2M-10.3%$-1.05+4.5%
2025-12-31$185.7M-28.3%$-0.90+4.7%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 4 filings
The $1.0 million decrease in interest expense, which was primarily due to the voluntary prepayment of principal on the Term Loan in February 2026, was partially offset by a $1.4 million decrease in interest income earned on our short-term investments in money…
10-Q · May 8, 2026
Demand and volumenegative · 4 filings
The increase was driven by strong demand in North America and EMEA, partially offset by lower contribution from China due to distributor ordering timing.
10-Q · May 8, 2026
Product pipeline and R&Dnegative · 4 filings
We expect our research and development costs will remain relatively consistent year-over-year in future periods, as a result of ongoing research and development initiatives.
10-Q · May 8, 2026
Restructuring and cost reductionsnegative · 4 filings
Restructuring Restructuring costs for the three months ended March 31, 2026 were attributable to the 2025 Corporate Realignment Plan.
10-Q · May 8, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

6.52-3.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for MRVI. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for MRVI. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind MRVI

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MOLNFiling-linked nameinvesteeFeb 26, 2026

2025 and Recent Developments Acquisition of Molecular Assemblies In January 2025, we completed the acquisition of assets from Molecular Assemblies, Inc.

FDXFedEx CorporationdistributorFeb 26, 2026

We ship a significant portion of our products to our customers through independent package delivery companies, such as World Courier, FedEx, UPS and DHL.

MSMorgan StanleylenderFeb 26, 2026

10.20 First Amendment to Credit Agreement, dated as of August 11, 2021, by Maravai Intermediate Holdings, LLC and Morgan Stanley Senior Funding, Inc.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

MRVI is currently a Follower in the organic co-movement group Industrial & Healthcare Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for MRVI; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.